This animal model develops all the features of human MetS, including visceral obesity, hypertension, dyslipidemia, glucose intolerance, secondary hypogonadism, i.e., low testosterone (T) and low gonadotropins (LH and FSH), and hepatic alterations as in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) [15,26]. Here, BRD2 is linked to metabolic dysfunction-associated steatotic liver disease.